CERo Therapeutics Adds Biotech Finance Veteran Eric Francois to Board
Event summary
- Eric Francois joins CERo Therapeutics' board on February 17, 2026
- Francois brings 25 years of biotech finance experience, including $300M+ in capital raises
- Former CFO of SCYNEXIS and director at CervoMed Inc.
- CERo Therapeutics focuses on novel phagocytic mechanism for cancer immunotherapy
The big picture
CERo Therapeutics strengthens its board with a finance veteran as it navigates the capital-intensive phase of clinical development. The move comes amid growing competition in cellular immunotherapy, where differentiated targeting mechanisms like CER-T could position the company for potential M&A interest or strategic partnerships.
What we're watching
- Capital Strategy
- How Francois' M&A and capital-raising expertise will shape CERo's funding approach.
- Clinical Progress
- The pace at which CER-1236 advances through clinical trials for hematologic malignancies.
- Board Influence
- Whether Francois' strategic direction aligns with CERo's long-term immunotherapy goals.
Related topics